FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361956278> ?p ?o ?g. }

• W4361956278 abstract "<div>AbstractPurpose:<p><i>PIK3CA</i> mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).</p>Patients and Methods:<p>Eligible patients had HER2-negative MBC with any number of prior chemotherapies. Phase I was 3+3 dose-escalation design with three dose levels of alpelisib (250, 300, and 350 mg) daily plus nab-paclitaxel 100 mg/m² administered on days 1, 8, and 15 every 28 days. Phase II was according to Simon's two-stage design. <i>PIK3CA</i> mutations in tumor/circulating tumor DNA (ctDNA) were assessed. Primary endpoints were recommended phase II dose (RP2D) and objective response rate (ORR). Additional endpoints included safety, pharmacokinetics, progression-free survival (PFS), and association of <i>PIK3CA</i> mutation with outcomes.</p>Results:<p>A total of 43 patients were enrolled (phase I, <i>n</i> = 13 and phase II, <i>n</i> = 30). A total of 84% had visceral disease and 84% had prior taxane. No dose-limiting toxicities occurred in phase I. RP2D was alpelisib 350 mg daily plus nab-paclitaxel 100 mg/m² on days 1, 8, and 15. Hyperglycemia (grade 3, 26% and grade 4, 0%), neutropenia (grade 3, 23% and grade 4, 7%), diarrhea (grade 3, 5% and grade 4, 0%), and rash (grade 3, 7% and grade 4, 0%) were the most common adverse events. Among 42 evaluable patients, ORR was 59% (complete response, 7% and partial response, 52%), 21% of whom had response lasting >12 months; median PFS was 8.7 months. A total of 40% of patients demonstrated tumor and/or ctDNA <i>PIK3CA</i> mutation; patients with tumor/ctDNA mutation demonstrated better PFS compared with those without mutation (11.9 vs. 7.5 months; HR, 0.44; <i>P</i> = 0.027). Patients with normal metabolic status had longer PFS compared with prediabetic/diabetic patients (12 vs. 7.5 months; <i>P</i> = 0.014). No pharmacokinetics interactions were detected.</p>Conclusions:<p>The alpelisib plus nab-paclitaxel combination was well tolerated and shows encouraging efficacy, especially in patients with <i>PIK3CA</i>-mutated tumor/ctDNA. The impact of metabolic status on response to this combination merits further investigation.</p></div>" @default.
• W4361956278 created "2023-04-05" @default.
• W4361956278 creator A5001281713 @default.
• W4361956278 creator A5006141217 @default.
• W4361956278 creator A5015247627 @default.
• W4361956278 creator A5021126232 @default.
• W4361956278 creator A5025517651 @default.
• W4361956278 creator A5026847618 @default.
• W4361956278 creator A5027304240 @default.
• W4361956278 creator A5028067020 @default.
• W4361956278 creator A5033625395 @default.
• W4361956278 creator A5037145238 @default.
• W4361956278 creator A5037148886 @default.
• W4361956278 creator A5043659065 @default.
• W4361956278 creator A5045652376 @default.
• W4361956278 creator A5050610841 @default.
• W4361956278 creator A5058830197 @default.
• W4361956278 creator A5065956795 @default.
• W4361956278 creator A5069182089 @default.
• W4361956278 creator A5071690283 @default.
• W4361956278 creator A5072093269 @default.
• W4361956278 creator A5072768670 @default.
• W4361956278 creator A5073415111 @default.
• W4361956278 creator A5074901638 @default.
• W4361956278 creator A5075889627 @default.
• W4361956278 creator A5085827064 @default.
• W4361956278 date "2023-03-31" @default.
• W4361956278 modified "2023-10-16" @default.
• W4361956278 title "Data from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer" @default.
• W4361956278 doi "https://doi.org/10.1158/1078-0432.c.6530748.v1" @default.
• W4361956278 hasPublicationYear "2023" @default.
• W4361956278 type Work @default.
• W4361956278 citedByCount "0" @default.
• W4361956278 crossrefType "posted-content" @default.
• W4361956278 hasAuthorship W4361956278A5001281713 @default.
• W4361956278 hasAuthorship W4361956278A5006141217 @default.
• W4361956278 hasAuthorship W4361956278A5015247627 @default.
• W4361956278 hasAuthorship W4361956278A5021126232 @default.
• W4361956278 hasAuthorship W4361956278A5025517651 @default.
• W4361956278 hasAuthorship W4361956278A5026847618 @default.
• W4361956278 hasAuthorship W4361956278A5027304240 @default.
• W4361956278 hasAuthorship W4361956278A5028067020 @default.
• W4361956278 hasAuthorship W4361956278A5033625395 @default.
• W4361956278 hasAuthorship W4361956278A5037145238 @default.
• W4361956278 hasAuthorship W4361956278A5037148886 @default.
• W4361956278 hasAuthorship W4361956278A5043659065 @default.
• W4361956278 hasAuthorship W4361956278A5045652376 @default.
• W4361956278 hasAuthorship W4361956278A5050610841 @default.
• W4361956278 hasAuthorship W4361956278A5058830197 @default.
• W4361956278 hasAuthorship W4361956278A5065956795 @default.
• W4361956278 hasAuthorship W4361956278A5069182089 @default.
• W4361956278 hasAuthorship W4361956278A5071690283 @default.
• W4361956278 hasAuthorship W4361956278A5072093269 @default.
• W4361956278 hasAuthorship W4361956278A5072768670 @default.
• W4361956278 hasAuthorship W4361956278A5073415111 @default.
• W4361956278 hasAuthorship W4361956278A5074901638 @default.
• W4361956278 hasAuthorship W4361956278A5075889627 @default.
• W4361956278 hasAuthorship W4361956278A5085827064 @default.
• W4361956278 hasBestOaLocation W43619562782 @default.
• W4361956278 hasConcept C112705442 @default.
• W4361956278 hasConcept C121608353 @default.
• W4361956278 hasConcept C126322002 @default.
• W4361956278 hasConcept C143998085 @default.
• W4361956278 hasConcept C2775930923 @default.
• W4361956278 hasConcept C2777292972 @default.
• W4361956278 hasConcept C2777511904 @default.
• W4361956278 hasConcept C530470458 @default.
• W4361956278 hasConcept C71924100 @default.
• W4361956278 hasConcept C90924648 @default.
• W4361956278 hasConceptScore W4361956278C112705442 @default.
• W4361956278 hasConceptScore W4361956278C121608353 @default.
• W4361956278 hasConceptScore W4361956278C126322002 @default.
• W4361956278 hasConceptScore W4361956278C143998085 @default.
• W4361956278 hasConceptScore W4361956278C2775930923 @default.
• W4361956278 hasConceptScore W4361956278C2777292972 @default.
• W4361956278 hasConceptScore W4361956278C2777511904 @default.
• W4361956278 hasConceptScore W4361956278C530470458 @default.
• W4361956278 hasConceptScore W4361956278C71924100 @default.
• W4361956278 hasConceptScore W4361956278C90924648 @default.
• W4361956278 hasLocation W43619562781 @default.
• W4361956278 hasLocation W43619562782 @default.
• W4361956278 hasOpenAccess W4361956278 @default.
• W4361956278 hasPrimaryLocation W43619562781 @default.
• W4361956278 hasRelatedWork W1753522318 @default.
• W4361956278 hasRelatedWork W181195935 @default.
• W4361956278 hasRelatedWork W1996698721 @default.
• W4361956278 hasRelatedWork W2071730404 @default.
• W4361956278 hasRelatedWork W2085123446 @default.
• W4361956278 hasRelatedWork W2154590531 @default.
• W4361956278 hasRelatedWork W2415253097 @default.
• W4361956278 hasRelatedWork W2468666928 @default.
• W4361956278 hasRelatedWork W2603750384 @default.
• W4361956278 hasRelatedWork W2688575822 @default.
• W4361956278 isParatext "false" @default.
• W4361956278 isRetracted "false" @default.
• W4361956278 workType "article" @default.